Merck Serono Launches MSdialog New, First of its Kind Software to Engage People with MS
A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease- modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.
MSdialog is Merck Serono’s innovative web-based software system for patients with relapsing- remitting multiple sclerosis receiving disease-modifying treatment Rebif® (interferon beta-1a).
MSdialog aims to optimise the time physicians and nurses have with their patients by focusing on relevant information and building an accurate picture of the patients’ health status over time.
“Engaging and empowering patients through knowledge and technology may have the potential to improve outcomes by allowing patients to help monitor their own disease,” said Dr Gavin Giovannoni, professor of Neurology at Barts and The London School of Medicine and Dentistry. “Innovations such as RebiSmart 2.0 & the MSdialog platform can do just that for multiple sclerosis; patients using these technologies will be more in touch with their own disease, which may lead to improved adherence and possibly even to improved outcomes and cost-savings.”
Consenting patients using RebiSmart 2.0 can upload their injection history wirelessly from their home, without the need for an internet connection, to MSdialog which can be accessed by their healthcare professional. The patient can complete periodic health report questionnaires based on published instruments and standard scales, such as the Multiple Sclerosis Quality of Life Inventory (MSQLI) and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire.[2,3] These are completed via a patient app or website and allow patients to track their health status over time.
Del Thomas, MS Clinical Nurse Specialist, Wye Valley NHS Trust, remarked: “The fact that MSdialog allows patients to regularly generate their own health reports will be an invaluable aid in vastly improving the conversations between MS nurses and their patients. It means that when patients come in for appointments, which can be 6 months or up to a year apart, we can easily and accurately see what concerns affect each patient the most. They don’t have to rely on memory alone. These could be concerns such as pain, mood, memory, or fatigue, as well as their injection history. This allows us to see a much clearer picture of their disease and really focus to optimise the consultation time together.”
Patients who use MSdialog can choose to receive email or SMS reminders to take their medication, and physicians can use MSdialog to generate reports and send email messages to patients and nurses. MSdialog can also be combined with Merck Serono’s patient support programme so that all healthcare professionals involved in the patient’s care can have visibility of the patients’ progress enabling an even more collaborative and holistic approach to care.
 The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee. MSQLI Multiple Sclerosis Quality of Life Inventory: A User's Manual. National Multiple Sclerosis Society. 1997.
 Simeoni M, Auquier P, Fernandez O, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008 Mar;14(2):219-30.
 Fernández O, Baumstarck-Barrau K, Simeoni MC, et al. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler. 2011 Oct;17(10):1238-49.
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance